177 related articles for article (PubMed ID: 12413931)
1. Pathology of borderline (low malignant potential) ovarian tumours.
Seidman JD; Ronnett BM; Kurman RJ
Best Pract Res Clin Obstet Gynaecol; 2002 Aug; 16(4):499-512. PubMed ID: 12413931
[TBL] [Abstract][Full Text] [Related]
2. The pathology of and controversial aspects of ovarian borderline tumours.
McCluggage WG
Curr Opin Oncol; 2010 Sep; 22(5):462-72. PubMed ID: 20531187
[TBL] [Abstract][Full Text] [Related]
3. Borderline epithelial tumours of the ovary--a retrospective analysis of 31 cases.
Kane SV; Bharadwaj R; Tongaonkar HB
Indian J Cancer; 1999 Mar; 36(1):18-31. PubMed ID: 10810551
[TBL] [Abstract][Full Text] [Related]
4. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators.
Seidman JD; Kurman RJ
Hum Pathol; 2000 May; 31(5):539-57. PubMed ID: 10836293
[TBL] [Abstract][Full Text] [Related]
5. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
Sieben NL; Macropoulos P; Roemen GM; Kolkman-Uljee SM; Jan Fleuren G; Houmadi R; Diss T; Warren B; Al Adnani M; De Goeij AP; Krausz T; Flanagan AM
J Pathol; 2004 Mar; 202(3):336-40. PubMed ID: 14991899
[TBL] [Abstract][Full Text] [Related]
6. Pseudomyxoma peritonei in women: a clinicopathologic analysis of 30 cases with emphasis on site of origin, prognosis, and relationship to ovarian mucinous tumors of low malignant potential.
Ronnett BM; Kurman RJ; Zahn CM; Shmookler BM; Jablonski KA; Kass ME; Sugarbaker PH
Hum Pathol; 1995 May; 26(5):509-24. PubMed ID: 7750935
[TBL] [Abstract][Full Text] [Related]
7. MDM2 Expression in Serous and Mucinous Epithelial Tumours of the Ovary.
Abdelaal SE; Habib FM; El Din AA; Gabal SM; Hassan NS; Ibrahim NA
Asian Pac J Cancer Prev; 2016; 17(7):3295-300. PubMed ID: 27509966
[TBL] [Abstract][Full Text] [Related]
8. Flow cytometry and AgNORs in benign, borderline, and malignant mucinous and serous tumours of the ovary.
Griffiths AP; Cross D; Kingston RE; Harkin P; Wells M; Quirke P
Int J Gynecol Pathol; 1993 Oct; 12(4):307-14. PubMed ID: 8253547
[TBL] [Abstract][Full Text] [Related]
9. Expression of a homeobox gene (SIX5) in borderline ovarian tumours.
Winchester C; Robertson S; MacLeod T; Johnson K; Thomas M
J Clin Pathol; 2000 Mar; 53(3):212-7. PubMed ID: 10823141
[TBL] [Abstract][Full Text] [Related]
10. Numerical abnormalities of chromosomes 1, 11, 17, and X are associated with stromal invasion in serous and mucinous epithelial ovarian tumours.
Evans MF; McDicken IW; Herrington CS
J Pathol; 1999 Sep; 189(1):53-9. PubMed ID: 10451488
[TBL] [Abstract][Full Text] [Related]
11. Analysis of CD44 expression in serous and mucinous borderline tumours of the ovary: comparison with cystadenomas and overt carcinomas.
Darai E; Walker-Combrouze F; Fauconnier A; Madelenat P; Potet F; Scoazec JY
Histopathology; 1998 Feb; 32(2):151-9. PubMed ID: 9543672
[TBL] [Abstract][Full Text] [Related]
12. Ovarian tumors of borderline malignancy (tumors of low malignant potential): a critical appraisal.
Prat J
Adv Anat Pathol; 1999 Sep; 6(5):247-74. PubMed ID: 10472378
[TBL] [Abstract][Full Text] [Related]
13. [Ovarian tumors of low malignant potential (borderline ovarian tumors)].
Luchian AM; Pricop M
Rev Med Chir Soc Med Nat Iasi; 2011; 115(2):438-45. PubMed ID: 21870737
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and treatment of borderline ovarian neoplasms "the state of the art".
Tropé C; Davidson B; Paulsen T; Abeler VM; Kaern J
Eur J Gynaecol Oncol; 2009; 30(5):471-82. PubMed ID: 19899396
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of peritoneal extensions for the diagnosis and management of serous ovarian borderline tumors].
Andrei S; Stolnicu S; Rădulescu D; Mocan S; Puşcaşu L
Rev Med Chir Soc Med Nat Iasi; 2006; 110(3):679-86. PubMed ID: 17571566
[TBL] [Abstract][Full Text] [Related]
16. Morphometry and digital AgNOR analysis in cytological imprints of benign, borderline and malignant serous ovarian tumours.
Stemberger-Papić S; Stanković T; Vrdoljak-Mozetic D; Versa-Ostojić D; Krasević M; Stifter S; Audy-Jurković S
Cytopathology; 2006 Dec; 17(6):382-9. PubMed ID: 17168922
[TBL] [Abstract][Full Text] [Related]
17. Stage-specific embryonic antigen 4 expression in epithelial ovarian carcinoma.
Ye F; Li Y; Hu Y; Zhou C; Hu Y; Chen H
Int J Gynecol Cancer; 2010 Aug; 20(6):958-64. PubMed ID: 20683402
[TBL] [Abstract][Full Text] [Related]
18. Serous and mucinous borderline ovarian tumours: differences in clinical presentation, high-risk histopathological features, and lethal recurrence rates.
Vasconcelos I; Darb-Esfahani S; Sehouli J
BJOG; 2016 Mar; 123(4):498-508. PubMed ID: 26705090
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas.
Shappell HW; Riopel MA; Smith Sehdev AE; Ronnett BM; Kurman RJ
Am J Surg Pathol; 2002 Dec; 26(12):1529-41. PubMed ID: 12459620
[TBL] [Abstract][Full Text] [Related]
20. Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas.
Rodríguez IM; Prat J
Am J Surg Pathol; 2002 Feb; 26(2):139-52. PubMed ID: 11812936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]